ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,762.50
0.79%
S&P ASX All Technology
3,075.90
0.03%
Brent Oil
81.02
0.27%
US Dollar vs AUD
1.50432
0.38%
Bitcoin
68,494.40
1.10%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Merck & Co Inc (0QAH)

  7. Merck & Co Inc (0QAH) News

0QAH

Merck & (0QAH)

Merck & Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QAH
DateTimeSourceHeadlineSymbolCompany
29/05/202423:22Alliance NewsAlliance NewsMerck & Co enhances ophthalmology portfolio with EyeBio acquisitionLSE:0QAHMerck & Co Inc
25/04/202421:13Alliance NewsAlliance NewsMerck & Co raises annual outlook thanks to first quarter boostLSE:0QAHMerck & Co Inc
16/03/202402:23Alliance NewsAlliance NewsIN BRIEF: Merck hails positive data on cervical cancer drug, KeytrudaLSE:0QAHMerck & Co Inc
21/02/202408:15Alliance NewsAlliance NewsMerck and Astellas drugs get priority review in US and JapanLSE:0QAHMerck & Co Inc
01/02/202423:57Alliance NewsAlliance NewsTOP NEWS: Merck books 2023 growth despite gefapixant rejection hitLSE:0QAHMerck & Co Inc
19/01/202422:29Alliance NewsAlliance NewsIN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon saleLSE:0QAHMerck & Co Inc
09/01/202401:20Alliance NewsAlliance NewsMerck to buy Harpoon Therapeutics for about USD680 millionLSE:0QAHMerck & Co Inc
18/12/202322:04Alliance NewsAlliance NewsAstellas, Merck, Pfizer celebrate US approval for Keytruda plus PadcevLSE:0QAHMerck & Co Inc
15/12/202319:41Alliance NewsAlliance NewsMerck gets US FDA nod for Welireg, as trial with Moderna bears fruitLSE:0QAHMerck & Co Inc
12/12/202304:56Alliance NewsAlliance NewsMerck reports mixed updates for cancer treatment, KeytrudaLSE:0QAHMerck & Co Inc
26/10/202322:17Alliance NewsAlliance NewsTOP NEWS: Merck hails Daiichi Sankyo partnership but will take chargeLSE:0QAHMerck & Co Inc
20/10/202316:06Alliance NewsAlliance NewsTOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug dealLSE:0QAHMerck & Co Inc
04/10/202303:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0QAHMerck & Co Inc
25/08/202301:24Alliance NewsAlliance NewsUPDATE: AstraZeneca, Merck & Co say Lynparza approved in JapanLSE:0QAHMerck & Co Inc
01/08/202321:49Alliance NewsAlliance NewsMerck & Co second quarter revenue up; profit falls acquisition costsLSE:0QAHMerck & Co Inc
16/06/202322:09Alliance NewsAlliance NewsMerck says latest trial data shows Keytruda meets survival endpointLSE:0QAHMerck & Co Inc
01/06/202322:44Alliance NewsAlliance NewsMerck and Astra's Lynparza prostate cancer treatment gets US approvalLSE:0QAHMerck & Co Inc
01/05/202321:35Alliance NewsAlliance NewsAstraZeneca "disappointed" with US ODAC's guidance on LynparzaLSE:0QAHMerck & Co Inc
27/04/202321:49Alliance NewsAlliance NewsMerck & Co beats on first-quarter revenue and hails "advancements"LSE:0QAHMerck & Co Inc
10/03/202323:31Alliance NewsAlliance NewsMerck's Keytruda combination sees positive results in cancer trialLSE:0QAHMerck & Co Inc
03/03/202304:20Alliance NewsAlliance NewsUS FDA to discuss AstraZeneca and Merck's Lynparza cancer drug comboLSE:0QAHMerck & Co Inc
24/02/202323:48Alliance NewsAlliance NewsIN BRIEF: EU refuses marketing recommendation for Merck's LagevrioLSE:0QAHMerck & Co Inc
03/02/202300:08Alliance NewsAlliance NewsTOP NEWS: Merck & Co annual net profit up but drops in fourth-quarterLSE:0QAHMerck & Co Inc
31/01/202303:35Alliance NewsAlliance NewsDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatmentLSE:0QAHMerck & Co Inc
21/12/202220:16Alliance NewsAlliance NewsAstraZeneca wins two new approvals in EU for cancer drugsLSE:0QAHMerck & Co Inc
21/12/202205:09Alliance NewsAlliance NewsFDA accepts Astellas, Seagen and Merck's combo for priority reviewLSE:0QAHMerck & Co Inc
15/12/202219:37Alliance NewsAlliance NewsAstraZeneca and Merck receive US FDA extension for Lynparza reviewLSE:0QAHMerck & Co Inc
23/11/202204:18Alliance NewsAlliance NewsIN BRIEF: Merck's Keytruda sees positive topline results in trialLSE:0QAHMerck & Co Inc
21/11/202223:53Alliance NewsAlliance NewsMerck buys biopharmaceutical firm Imago BioSciences for USD1.4 billionLSE:0QAHMerck & Co Inc
28/10/202200:29Alliance NewsAlliance NewsTOP NEWS: Merck & Co 3rd-quarter sales up; profit slips as costs riseLSE:0QAHMerck & Co Inc
 Showing the most relevant articles for your search:LSE:0QAH

Your Recent History

ASX
SUN
Suncorp
NASDAQ
MSFT
Microsoft
FX
AUDCAD
AUD vs CAD
ASX
WBC
Westpac Banking
ASX
CSL
CSL
ASX
NCM
Newcrest Mining
ASX
RIO
Rio Tinto
ASX
NAB
National Australia Bank
FX
GBPAUD
Sterling vs AUD
ASX
XAO
Australian SE All Ordina...
ASX
WPL
Woodside Petroleum
NYSE
KO
Coca Cola
ASX
XFL
S&P ASX 50
NYSE
VZ
Verizon Communications
FTSE
UKX
FTSE 100
ASX
MQG
Macquarie
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved